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ABSTRACT

Systemic administration of chemotherapeutics is associated with various side effects deriving from
accumulation in off-target sites and acute toxicity of the drugs. In the past decade, engineering
targeted drug delivery platforms arose as a novel paradigm to overcome such obstacles and
ultimately achieve advanced forms of chemotherapy.
This thesis reports successful syntheses of l-RSP, a redox-sensitive self-immolative polymer, and
DNS-SN38, thiol-sensitive SN-38 prodrug, as potential candidates for targeted drug delivery
platforms.
By covalently conjugating a redox-trigger (p-nitrobenzyl alcohol) and self-immolative linker (phydroxybenzyl alcohol) to the cyclization spacer (n-2-(hydroxyethyl)ethylene diamine), a novel
self-immolative monomer was obtained. Polymerization of the respective monomer yielded a
linear redox-sensitive polymer (l-RSP) that is capable of systemic degradation via sequential 1,6elimination and 1,5-cyclization reactions upon redox-stimulus. Ultimately, the polymer’s potential
for biomedical application was simulated through in vitro redox-triggered release of paclitaxel
from polymeric nanoparticles.
SN-38 (7-ethyl-10-hydroxy-camptothecin), a potent metabolite of irinotecan (CPT-11), has been
extensively investigated in the past for direct usage in order to fully exploit its cytotoxic potency.
Here, 2,4-dinitrobenzene sulfonyl (DNS) moiety was conjugated to SN-38 to furnish a thiolsensitive prodrug, denoted as DNS-SN38, that can be activated in the intracellular regions with
GSH abundance. Furthermore, due to strong electron-withdrawing potential of DNS, the inherent

fluorescence of SN-38 could be virtually quenched with intact conjugation. By investigating the
prodrug’s activation property upon thiol-sensitive trigger cleavage via fluorescence activation
and cytotoxicity against A2780 and mCherry+OCSC1-F2 cell lines, its vast potential as a viable
theranostic agent was demonstrated.
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PART 1
OVERVIEW
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ORGANIZATION OF THE THESIS
Herein, we propose synthesized l-RSP and DNS-SN38 as novel candidates for targeted drug
delivery for advanced chemotherapy. This thesis consists of three parts:
PART 1 briefly describes the idea of targeted drug delivery and its potential impact in the
advancement of conventional chemotherapy.
PART 2 describes linear redox-sensitive polymer (l-RSP). In the past decade, the selfimmolative biodegradable polymer arose as a novel paradigm for its efficient degradation
mechanism and vast potential for advanced biomedical applications. This study reports
successful synthesis of a novel biodegradable polymer capable of self-immolative backbone
cleavage. The monomer is designed by covalent conjugations of both pendant redox-trigger (pnitrobenzyl alcohol) and self-immolative linker (p-hydroxybenzyl alcohol) to the cyclization
spacer (n-2-(hydroxyethyl)ethylene diamine), which serves as the structural backbone. The
polymerization of the monomer with hexamethylene diisocyanate yields a linear redox-sensitive
polymer that can systemically degrade via sequential 1,6-elimination and 1,5-cyclization
reactions within an effective timeframe. Ultimately, the polymer’s potential for biomedical
application is simulated through in vitro redox-triggered release of paclitaxel from polymeric
nanoparticles.
PART 3 describes thiol-sensitive SN-38 prodrug (DNS-SN38). SN-38 (7-ethyl-10-hydroxycamptothecin), an active metabolite of irinotecan (CPT-11) and the most potent camptothecin
analogue, is of significant interest for direct usage in order to fully exploit its potency. In this
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study, 2,4-dinitrobenzene sulfonyl (DNS) was covalently conjugated as the redox-trigger to 10’ –
OH of SN-38 to yield a thiol-sensitive prodrug, denoted as DNS-SN38, with virtually quenched
fluorescence at 556 nm due to donor-excited photo-induced electron transfer (d-PeT). By
investigating DNS-SN38’s activation property upon thiol-sensitive trigger-cleavage via
fluorescence restoration and cytotoxicity against A2780 and mCherry+OCSC1-F2 cell lines, we
have validated its vast potential as a viable chemotherapeutic agent simultaneously capable of
real-time monitoring of SN-38.

3

TARGETED DRUG DELIVERY
According to an annual report of American Cancer Society, it is predicted that 1.6 million new
cancer cases will arise and 600,920 deaths will occur in 2018 in the United States alone. Despite
the tremendous efforts and a vast amount of financial resources that have been put into fighting
cancer, the disease still remains as a major health problem that affects not only the United States,
but the whole world. Although cancer may not be the most frequent cause of death, it is
commonly recognized as the most fatal disease, to which no complete treatment is available once
it steps into more advanced stages.
Currently, chemotherapy is considered to be one of the more effective clinical options against
cancer in more advanced stages. However, the respective treatment is significantly hampered by
adverse side effects like multidrug resistance (MDR) and systemic toxicities that affect not only
the tumor cells, but also the normal cells. In order to effectively overcome these obstacles, the
development of targeted drug delivery systems arose as a novel paradigm in the pharmaceutics
industry.
Targeted drug delivery platform is a special type of platform that is designed to achieve selective
delivery of drugs to either site of action or site of absorption. By preventing drug accumulation
in non-targeted sites, the treatment efficacy can be significantly improved and associated side
effects can be reduced. Ideally, these systems should be non-toxic, biocompatible, biodegradable
or bioeliminable and are available in various forms such as dendrimer or polymer, prodrug,
antibody drug conjugate, peptide drug conjugate, and liposome. The most significant property of
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these systems is that they aim to exploit physiologic biomarkers that are associated with specific
diseases for targeting: pH changes, redox status, reactive oxygen species (ROS), overexpressed
enzymes, and proteins.

5

PART 2:

NOVEL BIODEGRADABLE POLYMER WITH REDOX-TRIGGERED
BACKBONE CLEAVAGE THROUGH SEQUENTIAL 1,6-ELIMINATION AND
1,5-CYCLIZATION REACTIONS
C.‐H. Whang, K. S. Kim, J. Bae, J. Chen, H.‐W. Jun, S. Jo, Macromol. Rapid Commun. 2017, 38,
1700395.
© WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2017.
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CHAPTER 1: INTRODUCTION
Over the past two decades, a significant progress has been made towards the development
of synthetic biodegradable polymers for advanced biomedical applications such as tissue
regeneration and controlled drug delivery.1 A number of biodegradable polymers could be
engineered using various approaches to apply biocompatible materials into platform design.
Although the respective polymers indeed displayed successful degradation upon
hydrolysis, the lack of specificity in location as well as inconsistency in degradation rate
have limited their translation into practical applications. In light of this, much research in
recent years has focused on optimizing triggers that are responsive to different stimuli with
the ambition to effectively control polymer degradation.2
Among the corresponding functional groups, p-nitrobenzyl alcohol (p-NBA) has been
widely utilized for its rapid electron cascade mechanism that is activatable by electronic
reduction of its aryl nitro (NO2) group. Upon activation, p-NBA trigger converts into a 1,6elimination spacer called p-aminobenzyl alcohol (p-ABA).3 The redox-sensitive polymers
are currently of significant interest in the controlled drug delivery research for targeting
cancer cells that show notably altered redox environment compared to normal cells.4 As
this difference in redox capacity also relates to positive correspondence towards tumor
progression and elevated drug resistance, it is accepted to be one of the more viable targets
for selective delivery of drug molecules.5
With such stimuli-sensitivity in hand, furnishing efficient and predictable mechanism of
polymer degradation became paramount for the advancement of novel polymer material
7

intended for drug delivery. In the past decade, the so-called ‘self-immolative’ system
quickly arose as a novel paradigm in the research field for its extremely efficient dominolike disassembly mechanism. The respective system shows much resemblance to the
biological system’s signal transduction and amplification processes, where a relatively
small number of hormone molecules are capable of inducing significant cellular responses
through a cascade of amplification steps. The analogous synthetic system mimics such
processes as it is designed to degrade from head-to-tail upon cleavage at the focal point of
a molecule.6
The initial form of the self-immolative polymer was a dendrimer theoretically intended
for significant functional amplification through highly-ordered dendritic chain.7 However,
due to complexity in synthesis for such molecule to achieve dramatic amplification, current
interest in achieving similar advantage resides in synthesizing linear polymeric system for
its facile one-step polymerization with appropriately designed monomer.8 Several linear
biodegradable polymers with self-immolative property have been synthesized by several
groups for effective amplification of stimuli-sensitivity in mind. The first reported of such
system was synthesized by Shabat’s group, in which the whole compound could be
degraded entirely by 1,6-elimination decarboxylation reactions. Considering their polymer
chain consisted of over 15 monomer units, its functional efficacy could be well displayed.9
Since then, tremendous progress has been made in order to translate such innovative
approach into various applications including drug delivery and biosensors. For example,
nanoparticle drug delivery application was demonstrated through preparation of
amphiphilic block copolymer by conjugating hydrophilic end caps on a hydrophobic selfimmolative polymer.10
8

In this article, we report on the synthesis of linear redox-sensitive polymer (l-RSP) with
self-immolative degradation mechanism. The design of our monomer comprises of three
components that can be readily degraded by a cascade of irreversible electron-pushing
mechanisms induced by focal point reduction. One of the significances of this work resides
in

the

introduction

of

a

new

self-immolative

polymer

backbone,

n-2-

(hydroxyethyl)ethylene diamine (N-2-HED), which appends to the very limited number of
currently available backbones. To this backbone, a redox trigger, p-NBA, and selfimmolative linker, p-HBA, are covalently conjugated to its primary amine and secondary
amine, respectively (Scheme 1). The incorporation of p-NBA as the redox-trigger
highlights the polymer’s functional variation from other redox-sensitive systems that
primarily utilize disulfide bridge reduction. This nitroaryl trigger allows potential
enzymatic reduction, including nitroreductases (NTR), which are commonly expressed in
pathological bacteria.11
Through sequential 1,6-elimination decarboxylation and 1,5-intramolecular cyclization
mechanisms, the respective polymer system is expected to degrade into biocompatible
fragments for potential biomedical applications.
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CHAPTER 2: EXPERIMENTAL
MATERIALS.
4-nitrobenzyl alcohol (p-NBA) and 4-nitrophenyl chloroformate (4-NPC) were purchased from
Sigma-Aldrich (St. Louis, MO); n-(2-hydroxyethyl)ethylene diamine (N-2-HED) and 4hydroxybenzyl alcohol (p-HBA) was purchased from Alfa Aesar (Ward Hill, MA); polystyrene
standards were purchased from Polysciences, Inc. (Warrington, PA); paclitaxel (PTX) was
purchased from LC Laboratories® (Woburn, MA, USA); All other chemicals and solvents were
purchased from Fisher Scientific (Pittsburgh, PA).

I.

Synthesis of Linear Redox-Sensitive Polymer (l-RSP) (Schemes 1 and S1)
I.1. Synthesis and 1H NMR Characterization of (NBA-HED).
p-NBA (12 mmol) was dissolved in 10 ml of anhydrous DCM, to which excess amount of pyridine
was added (50 mmol). Next, 4-NPC (10 mmol), dissolved in 10 ml of anhydrous DCM, was added
to the reaction mixture in a drop-wise fashion over 30 minutes at 0oC. The mixture was then left
to stir at room-temperature for 5 hours. After checking the reaction progress using TLC
(EtOAc:Hexane = 8:2), one-pot synthesis was carried out. In a separate round-bottom flask, N-2HED (50 mmol) was dissolved in 10 ml of anhydrous DCM, to which excess amount of pyridine
was added again. The first reaction batch was then added drop-wise over 30 minutes at 0oC. After
stirring for >16 hours at room-temperature, the crude product was obtained by extraction (0.1 M
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NaOH and brine) and evaporation under reduced pressure. The solid product was further purified
by recrystallization (EtOAc:Ethyl Ether = 5:5), yielding white solid powder.
% Yield = 60%; 1H NMR (400 MHz, CDCl3) δ ppm: 8.21 (2H, d), 7.51 (2H, d), 5.52 (-OH, br.),
5.19 (2H, s), 3.69 (2H, t), 3.36 (2H, m), 2.83 (4H, m).
I.2. Synthesis and 1H NMR Characterization of (HBA-NPC).
p-HBA (10 mmol) was dissolved in 10 ml of anhydrous THF in a reaction flask to which excess
TEA (30 mmol) was added. To the reaction mixture, 4-NPC (10 mmol), dissolved in 10 ml of
anhydrous THF, was added in drop-wise fashion over 90 minutes at 0 oC. After the addition was
complete, the reaction mixture was left to stir for 2 hours at room temperature. The resulting
organic phase was then evaporated under reduced pressure, to which DCM was added for
extraction with water and brine. The crude solid product was further purified by recrystallization
(Toluene:DCM) to yield light-yellow solid powder.
% Yield = 76 %; 1H NMR (400 MHz, CDCl3) δ ppm: 8.33 (2H, d), 7.50 (2H, d), 7.46 (2H, d), 7.29
(2H, d), 4.74 (2H, s).
I.3. Synthesis and 1H NMR Characterization of (Redox-Sensitive Monomer).
NBA-HED (4.2 mmol) was dissolved in 10 ml of anhydrous THF, to which excess pyridine (20
mmol) was added. After 15 minutes of stirring at room temperature, HBA-NPC (5.0 mmol),
dissolved in THF, was added to the reaction mixture drop-wise at 0oC. The solution was proceeded
under reflux at 50oC with vigorous stirring for 24 hours. The reaction progress was checked using
TLC and the resulting organic phase was concentrated under reduced pressure for purification
through flash column chromatography (EtOAc:Hexane = 7:3). The crude product was then
recrystallized (DCM) into white solid powder. The 1H NMR spectrum is shown in Figure S2 with
appropriate proton assignments.
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% Yield = 54%; 1H NMR (400 MHz, CDCl3) δ ppm: 8.15 (2H, d), 7.47 (2H, d), 7.31 (2H, t), 7.05
(2H, d), 5.48 (NH, s), 5.20 (2H, d), 4.68 (2H, s), 3.88 (2H, s), 3.66-3.55 (6H, m).
I.4. Polymerization of NBA-HED-HBA using hexmethylene diisocyanate (l-RSP).
The monomer was dissolved in 10 ml of anhydrous THF, to which diluted HMDI (in 5 ml of
anhydrous THF) was added in drop-wise fashion over 15 minutes at 0oC. After stirring for 15
minutes, a drop of dibutyltin diaurate was added into the mixture at the same temperature. The
reaction mixture was then left to stir overnight at room temperature. The polymer was extracted
through precipitation in excess of cold hexane as white gooey solid, which hardened into
crystalline-like solid after overnight vacuum evaporation.
II.

Polymer Characterization via 1H NMR and GPC.
The % yield of polymerization reaction was determined to be 73%. The chemical structure of the
synthesized polymer was analyzed and confirmed through 1H-NMR spectrum with Bruker Avance
400 MHz spectrometer, in which (CD3)2SO:D2O (v/v 6:1) was used as the reference solvent. The
corresponding spectrum is shown in Figure S3 (with corresponding proton assignments), where
peak-broadening – compared to that of the monomer – as well as HMDI proton peaks were
observed. The molecular weight of the polymer, in weight-average (Mw), was determined through
gel permeation chromatography (GPC) system purchased from (Waters, Milford, MA), which was
equipped with Waters 1525 binary pump, Waters 717plus auto sampler, Waters 2414 refractive
index detector, and Phenogel 10µ 10E3A column (300x7.8 mm, 10 micron). The mobile phase
was composed of 100% HPLC-grade THF, eluting at a flow rate of 1.0 mL/min. at 25 oC. Using
Breeze 3.3 software, a calibration curve (R2 = 0.999) was constructed from the polystyrene
standards ranging from 1,200 to 50,000 g.mol-1.

III.

Preparation of Polymeric Nanoparticles and Encapsulation of PTX.
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The preparation of redox-sensitive polymeric nanoparticles was carried out by single oil-in-water
nanoemulsion method. First, 25 mg of the polymer was completely dissolved in 2 ml of
CH2Cl2:MeOH (19:1) solution, which was slowly added into 20 mL of PVA (1% w/v)-PBS buffer
solution (pH = 7.4) with constant stirring at room-temperature. Next, the mixture was emulsified
by probe sonication for one minute using Sonics Vibra Cell, CV18. The solution was then left to
stir overnight at room-temperature for evaporation of the organic phase. After filtering out large
particles using 0.45 µm filter, the nanoparticles were washed with DDI water (deionized-distilled)
twice and re-dispersed in mannitol-water solution (10 mg). The solution was then lyophilized to
obtain white solid particles. The PTX-encapsulation process was carried out in the same manner,
in which 2.5 mg of PTX was dissolved along with polymer in the organic solution before the
emulsion step.
IV.

Characterization of Polymeric Nanoparticles via Dynamic Light Scattering (DLS),
Transmission Electron Microscopy (TEM) and High-Performance Liquid Chromatography
(HPLC).
Using Zetasizer Nano ZS purchased from Malvern Instruments (Malvern, UK), the size
distribution (by intensity) of the polymeric nanoparticles was determined via dynamic light
scattering (DLS) for both blank (Z-average diameter = 210.3 d.nm; PDI = 0.158) and PTX-loaded
(Z-average diameter = 232.3 d.nm; PDI = 0.296) samples (Figure S1). The respective particles
were also characterized using TEM using Tecnai T12 microscope (FEI, Hillsboro, OR) operating
at 80.0 kV. All samples were sonicated briefly before being mounted on a carbon-coated Formvar
cooper grid (400 mesh). After appropriate drying process, the samples were negatively-stained
with uranyl acetate (2% w/v) prior to imaging. The PTX-loading content (w/w) of 2.3% was
determined by completely dissolving the nanoparticles in THF and quantitating the drug
13

concentration in the solution using the PTX-calibration curve (R2=0.9998) constructed using
Waters HPLC system (λDetection = 230 nm) with Waters 1525 binary pump, Waters 717plus auto
sampler, Waters 2487 UV detector, and Phenomenex Luna C18 column (150x4 60 mm, 5 micron).
The mobile phase was ACN:H2O mixture (55:45, v/v) at a flow rate of 1.0 ml/min.
V.

In Vitro Redox-Triggered Release Study

V.1. PTX Release Study.
The PTX release from polymeric nanoparticles was studied under 200-molar excess of sodium
dithionite (to estimated number of p-nitrobenzyl trigger). Drug-loaded nanoparticles (PTX = 34.5
µg) were suspended in 2.0 mL of PBS buffer (pH 7.4) – 0.8 M sodium salicylate solution. The
reduced sample contained sodium dithionite, while the control sample did not. Both samples were
incubated at 37oC for 24 hours, during which sampling (centrifugation 13.0 K RPM for 15 minutes
and aliquot collection) was carried out at pre-determined time-points (hrs.): 0, 1, 3, 6, 12, 24. The
step-wise release trend was also studied using the respective nanoparticles. However, the particles
were introduced to excess sodium dithionite condition after 12 hours of incubation in the same
release medium (and temperature). The samplings were carried out in the same manner at
following time-points (hrs.): 0, 1, 3, 6, 12, 16, 24. The volume of the release medium was
initialized after every sampling. The HPLC system flow rate (ACN:H2O = 55:45; v/v) was set at
1.0 mL/min. and λDetection at 230 nm.
V.2. p-HBA Release Study.
The release of p-HBA from reduced polymer sample was examined via HPLC analysis. 5 mg of
the polymer was dissolved in 1.4 mL of DMSO:H2O (6:1; v/v) solution, to which 200-molar excess
of sodium dithionite was added. The sample was vigorously vortexed and then incubated at 37 oC
for 24 hours until sampling (centrifugation and aliquot collection) with the mobile phase –
14

MeOH:H2O:2-Propanol (35:55:10). The HPLC system flow rate was set at 0.5 mL/min. and
λDetection at 270 nm. The effect of sodium dithionite on 4-HBA stock sample was also tested (Figure
S4).
VI.

Polymer Biocompatibility Study
Polymer biocompatibility was investigated using live and dead (viability/cytotoxicity) kit and
CyQuant cell proliferation assay (Invitrogen, Carlsbad, USA). Specifically, bone marrow
mesenchymal stem cell (hMSCs) were purchased from Lonza, Inc. (Walkersville, MD). hMSCs
within passage numbers 4 were used for the experiments and grown with MSCGM™
Mesenchymal Stem Cell Growth medium kit from Lonza, Inc. The hMSCs were seeded onto 48
well plate at a cell seeding density of 10,526 cells/cm2 (1x104 cells) per well. After the cells were
attached to the wells, different concentrations of polymer were applied. The polymer
concentrations tested were: (1) 0 mg/mL (control), (2) 0.1 mg/mL, (2) 0.01 mg/mL, (3) 0.0001
mg/mL. Each condition was conducted in 6 replicates including 3 replicates for CyQuant cell
proliferation assay and 3 replicates for live and dead cell (viability/cytotoxicity) imaging. Cell
cultures in the plate were maintained under standard culture conditions (37 °C, 95% relative
humidity, and 5% CO2). The live and dead viability/cytotoxicity kit was performed on day 1 and
day 4 of polymer treatments. The live and dead viability/cytotoxicity kit can provide two color
fluorescence to indicate viable cells (green fluorescence) and dead cells (red fluorescence). The
live and dead cell imaging was performed using fluorescent microscope (Nikon, USA). After
live and dead assay imaging, the samples were collected and stored at -80 °C for cyquant
proliferation assay based on the manufacturer’s protocol. In the process of CyQuant cell
proliferation assay, the fluorescence intensity of samples was measured using a microplate reader
(EL×800, BIO-TEK Instrument, VT) at 480 nm (excitation) and 520 nm (emission). Finally, the
15

fluorescence intensity was converted to the cell number by using the cell number standard curve.
The results (Figures S6 and S7) proved that the polymer treatment did not induce cytotoxicity to
hMSCs at indicated polymer concentration range (0 to 0.1 mg/mL) as cell proliferation was not
negatively impacted by the polymer presence.
VII.

Statistical Analysis
The triplicated measurements were presented as mean ± standard deviation (SD) . The student’s ttest analysis was applied for the experimental data, where statistical significance was considered
for p < 0.05.

Scheme S1 Synthesis scheme for intermediates and monomer.
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Figure S1 Polymeric nanoparticle size determination via DLS.

Figure S2 1H NMR (400 MHz, CDCl3) spectrum of the monomer with proton assignments.
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Figure S3 1H NMR (400 MHz, (CD3)2SO:D2O = 6:1) spectrum of the polymer with proton
assignments.
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Figure S4 HPLC detection (λDetection = 270 nm) of p-HBA release from redox-triggered polymer
degradation. (A) stock p-HBA sample; (B) stock p-HBA sample with sodium dithionite; (C)
polymer sample after 24 hours of degradation with sodium dithionite.
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Figure S5 Overlay of DLS plots showing decreasing particle size over time.
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Figure S6 Cell number (%) for each well was determine in comparison to the control (without
polymer treatment) group. (a) Day 1 of treatment; (b) Day 4 of treatment. Error bars represent ±
standard deviation (n = 3).
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Figure S7 Live and dead assay images of (a) control at day 1; (b) hMSCs treated with 0.1 mg/mL
polymer at day 1; (c) hMSCs treated with 0.01 mg/mL polymer at day 1; (d) hMSCs treated with
0.0001 mg/mL polymer at day 1; (e) control at day 4; (f) hMSCs treated with 0.1 mg/mL polymer
at day 4; (g) hMSCs treated with 0.01 mg/mL polymer at day 4; (h) hMSCs treated with 0.0001
mg/mL polymer at day 4. Scale bar: 200 µm.
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CHAPTER 3: RESULTS AND DISCUSSION
Polymer Design and Characterization
A redox-sensitive polymer, synthesized primarily by carbamate bonds, was successfully
obtained from a monomer consisting of p-NBA trigger. Initially, NBA-HED was
synthesized by conjugating activated p-NBA (with 4-nitrophenyl chloroformate) to N-2HED. Next, similarly activated p-HBA was conjugated to NBA-HED to yield a redoxsensitive monomer (Scheme S1, Supporting Information). This monomeric compound was
then polymerized into polyurethane with pendant p-NBA using hexamethylene
diisocyanate (Scheme 1 (a)). The synthesis yield of the polymer was calculated to be 73%
after precipitation in hexane. Using gel permeation chromatography (GPC) system (Waters,
Milford, MA), the weight-average (Mw) molecular weight and PDI of the polymer were
determined to be around 9,815 Da and 2.05, respectively.
The triggered-fragmentation of the polymer is expected to start once the end aryl nitro
group of pendant p-NBA reduces into amine, which can spontaneously initiate a cascade
of self-immolative processes throughout all the repeating units (Scheme 1 (b)). First, the
trigger moiety detaches from the backbone’s primary amine through 1,6-elimination
decarboxylation, resulting in p-aminobenzyl alcohol (p-ABA) and CO2 fragments. Next,
the unmasked primary amine readily causes a 1,5-intramolecular cyclization of the
backbone, leading to its cleavage from the compound. The electron-pushing cascade then
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continues on through p-HBA in a similar manner, ultimately resulting in systemic
degradation of the polymer within an effective timeframe.
Redox-Triggered Degradation Monitored via 1H NMR
In order to confirm our hypothesis, the electronic reduction-induced structural changes
of the synthesized polymer were observed and analyzed through 1H NMR (400 MHz,
(CD3)2SO:D2O = 6:1 v/v) measurements, where 200-fold molar excess of sodium dithionite
(Na2S2O4) over aryl nitro groups was used as the reductant. In Figure 1, observed proton
shifts clearly suggest the polymer degradation sequence in accordance with our prediction.
The figure shows that the initial shifts occurred for peaks (a) and (b), which represent
benzylic protons of the nitrobenzyl trigger – assigned in Figure S3, Supporting Information.
As observed in spectrum B of the figure, the corresponding peaks shifted up-field compared
to their initial chemical shifts in spectrum A. This is most-likely in response to the
electronic re-shielding effect brought upon by the reduction of electron-withdrawing nitro
group into an electron-donating amine group.12 The consequent electron cascade resulting
from such reduction then led to the formation of p-ABA and p-HBA, which was represented
by the merging of their methylene proton peaks (c) and (d) – assigned on spectrum C. Such
merging is possible, as the electronic environments for the corresponding methylene
protons of each group become virtually equal when both moieties are cleaved off to be
independent from the polymer backbone. This claim is supported by several studies, in
which the corresponding protons were assigned to be around 4.50 ppm (1H NMR) for both
p-HBA13(a) and p-ABA13(b).
Furthermore, the rearrangement of peak (e) – which represents 4 protons of 3’ and 4’
methylene groups of N-2-HED backbone (shifts assigned in Figure S3, Supporting
24

Information) – into a single peak seen on spectrum C suggests that the 1,5-cyclization
fragment was indeed created during the process. The formation of 2-imidazolidinone ring
(Scheme 1 (b)) could provide similar electronic environment to those protons.14 This is
analogous to the previous explanation for merging of (c) and (d) peaks.
The probable reason for relatively slow formation of the cyclization fragment compared
to the initial 1,6-elimination reaction may be the distance that the exposed amine group
must cyclize in order to reach the carbamate linkage connecting p-HBA and the backbone.
Here, poor electrophilicity of the carbamate bond or slight protonation of amine in aqueous
environment can further slow the reaction down, as suggested previously.15 This issue is a
prevalent theme among the molecules aiming degradation through intramolecular
cyclization based on n,n’-dimethylethylenediamine spacer, as some are reported to require
days to reach complete disassembly.15,16 Therefore, it is advisable to avoid carbamate
linkage when incorporating cyclization reactions as the sole routine for targeting rapid
degradation. As successfully demonstrated previously, converting such linkage into either
carbonate or thiocarbonate could effectively address the issues mentioned above and
thereby induce significantly faster degradation.15 In regards to our polymer, however, the
alternating mechanisms of rapid 1,6-elimination reaction and 1,5-intramolecular
cyclization based on N-2-HED prove to be effective in tuning the overall degradation
kinetics, as the process completes within 24 hours according to our 1H NMR monitoring.
Polymeric Nanoparticle Characterization via DLS and TEM
After observing redox-triggered structural changes of the polymer through 1H NMR,
polymeric nanoparticles were prepared through single oil-in-water emulsion method using
poly(vinyl alcohol) (PVA) as the emulsion stabilizer to test chemical release in a redox25

sensitive manner. With Zetasizer Nano ZS (Malvern, UK), the particle size distribution was
determined by dynamic light scattering (DLS) method, where the Z-Average diameter was
determined to be 210.3 d.nm. (PDI = 0.158) for blank particles and 232.3 d.nm (PDI =
0.296) for PTX-loaded particles (Figure S1, Supporting Information).
The redox-sensitivity of the polymer was then further characterized using the respective
nanoparticles by suspending them in reductive aqueous environment (dissolved excess
amount of Na2S2O4). As shown in Figure 2 (a), the addition of reducing agent led to rapid
increase in particle size, up to maximum of 623.2 d.nm. within 80 minutes of reduction.
This extreme behavior was in parallel with previous reports on redox-sensitive
micelles/nanoparticles, in which the experiments were conducted in similar manners. As
explained in those studies, the trend may be explained by the solubility reversal of the
polymer core’s hydrophobic nature into hydrophilic nature, due to successful unmasking
of amine group in its backbone.1(a),17 The consequent hydration of the particles induced
drastic swelling, which can be correlated with observed particle size increase.
Also, in previous studies on polymer particulate encapsulation of paclitaxel (PTX), it
has been suggested that the particle size may increase more than two-folds due to
hydrophobic interactions between drug molecules and polymer core.18 However, in case of
our polymeric nanoparticle encapsulation of PTX, the respective size increase was
insignificant as Z-average diameters of PTX-encapsulated and blank particles displayed
near-identical results (Figure S1, Supporting Information). This negligible difference may
be explained by our nanoparticles’ relatively low drug-loading content of 2.3% (w/w)
compared to as high as 18% (w/w) for amphiphilic polymer micellar-encapsulation of PTX
using a redox-responsive polymer based on quinone propionic acid.1(a) As enhanced
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hydrophobicity of particle’s core is positively correlated to the increased drug loading
efficiency and low drug release, this suggested that our polymer core exhibited relatively
low hydrophobicity.19
The transmission electron microscopy (TEM) images of our nanoparticles indeed
showed morphologies that qualitatively supported such negligible size difference between
blank and drug-loaded particle samples, in which both displayed stable spherical shape
(Figure 2 (b)). The slight size estimation difference between the two methods (TEM and
DLS) may simply be explained by the variation in physical conditions provided for the
particles. The hydrodynamic particle size determined by DLS is accepted to be always
greater than the estimation of TEM, as aqueous suspension in DLS provides solvation-layer
coating around the particles.20
It should be noted that the hydrodynamic estimation may be considered more relevant
to potential biomedical applications, as it mimics the biological conditions that particles
must be optimized to. For example, in designing polymeric particles for cancer-selective
drug delivery, procurement of nanoscopic size range is imperative as it enhances the
particles’ tendency to selectively accumulate in the tumor tissues via enhanced permeability
and retention (EPR) effect.21 Although there are slight variations in accepted ranges for the
particles to capitalize EPR effect, 10 nm to 100 nm range is generally known to be most
ideal for avoiding both kidney and reticuloendothelial clearances.22 In this sense, our
nanoparticles have room to improve in further minimizing its size distribution. One
approach towards achieving such optimization may be through PEGylation at the polymer
ends to yield an amphipathic compound which can self-assemble into micelles without the
aid of surfactant(s). The corresponding modification may not only significantly reduce the
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overall hydrodynamic size distribution, but also prevent inevitable hydrophobic
aggregation of the particles, as PEG outer-layer minimizes electrostatic attractions.23
Redox-Triggered PTX-Release Study via HPLC
In order to further confirm the polymer’s redox-sensitivity, in vitro PTX release from
the drug-loaded nanoparticles in the presence of sodium dithionite was quantified using
high-performance liquid chromatography system (Waters, Milford, MA) (Figure 3). The
release trends for both control (without sodium dithionite) and reduced samples were
monitored over the course of 24 hours at following predetermined time points: 1, 3, 6, 12,
and 24 hours. (Figure 3 (A)). As depicted in the figure, the reduction clearly induced
significantly faster release of the drug from the particles. By the 24-hour mark, the reduced
polymer nanoparticles could release around 84% of the encapsulated drug content, while
the control sample release remained around 37%. Here, our control sample’s relatively high
drug release can be attributed to aforementioned low hydrophobicity of our polymer core,
which could enhance drug diffusion to PTX-soluble release medium containing 0.8 M
sodium salicylate.24 The rapid release induced by reduction was also displayed in a stepwise fashion (Figure 3 (B)), where the reducing agent was applied after 12 hours of particle
incubation in the same release medium. As this plot shows, a dramatic increase in release
rate was observed once the reduction occurred. The reduction-mediated release trends
shown through these in vitro studies were indeed comparable to the results of the past
studies.1(a),17
Furthermore, the release of p-HBA could be also detected from the reduced polymer
sample via HPLC (Figure S4, Supporting Information). This detection suggested that our
polymer backbone was indeed cleaved by the alternating mechanism involving 1,628

elimination of p-HBA as originally hypothesized. Taken together, it was clear that the
reducing agent was able to cause physicochemical changes on our polymer for ultimately
desired degradation. Thus, this approach may be further applied for the nanoparticle
preparation of other biodegradable polymers suitable for biomedical applications.

(a)

(b)

Scheme 1 (a) Polymerization scheme to synthesize l-RSP (b) Focal point reduction-induced
disassembly of the l-RSP.
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Figure 1 1H NMR (400 MHz, (CD3)2SO:D2O = 6:1 v/v) monitoring of structural changes the
polymer experiences upon reduction. (A) control, without sodium dithionite; (B) 1 hour of
reduction; (C) 24 hours of reduction.
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(a)

(b)

Figure 2 (a) Redox-induced size increase of polymeric nanoparticles monitored via DLS; (b) TEM
images of nanoparticles (Right) PTX-Encapsulated (Left) Drug-free particles. Error bars represent
± standard deviation (n = 3).
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Figure 3 Redox-triggered PTX-release profiles of nanoparticles monitored via HPLC (λDetection =
230 nm). (a) reduced group compared to the control (non-reduced) group; (b) reduction (sodium
dithionite) applied at 12-hour mark. Error bars represent ± standard deviation (n = 3).
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CHAPTER 4: CONCLUSIONS
In conclusion, we reported successful synthesis and characterization of a novel redox-sensitive
polymer with spontaneous backbone cleavage through alternating 1,6-elimination and 1,5intramolecular cyclization reactions. Simple covalent conjugations of redox-trigger (p-NBA),
1,5-cyclization spacer (N-2-HED), and self-immolative linker (4-HBA) yielded a redox-sensitive
monomer that was polymerized into a biodegradable polyurethane. In both qualitative and
quantitative manners, polymer characterizations were carried out to confirm its redox-triggered
self-immolative disassembly.
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PART 3:
SYNTHESIS OF DNS-SN38, A NOVEL THIOL-SENSITIVE SN-38 PRODRUG FOR
BIMODAL THERAPY.
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CHAPTER 1: INTRODUCTION
SN-38 (7-ethyl-10-hydroxy-camptothecin), an active metabolite of irinotecan (CPT-11),
is considered to be the most potent antineoplastic agent among the camptothecin (CPT)
derivatives. The CPT analogues are known to act as inhibitors of topoisomerase 1 (Top1), which plays a crucial role in relieving the torsional strain in DNA.1 In clinical
applications, CPT-11 has been found effective against various types of cancer, including
colorectal, lung, and ovarian cancers.2 The therapeutic efficacy of CPT-11 is considered
to be directly related to its metabolic conversion into SN-38 by carboxylesterases 1 and 2,
as SN-38 exhibits potency of up to 1000-fold relative to that of CPT-11.3 Due to
relatively low conversion rate (<10%) 4 and significant interpatient discrepancies in
carboxylesterase efficacy 4, however, direct usage of SN-38 is accepted as an ideal path to
fully exploit its cytotoxic potency. Despite this, the translation of SN-38 into an
appropriate chemotherapeutic option has been hampered by a number of limitations
deriving from its low solubility and acute toxicity.
In the past decade, targeted prodrug strategy has gained a considerable attention in the
biomedical field for its advantageous traits over conventional drugs used in the clinic.
Through covalent conjugation of functional moieties that are sensitive to biological
signals found in the disease sites, such as pH changes 5, reactive oxygen species (ROS) 6,
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enzyme overexpression 7, and elevated biothiol levels 8, various innovative prodrug
systems could be engineered to display enhanced activation efficiency as well as site
specificity in drug release. In particular, such strategy has been extensively implemented
on anticancer therapeutics that are prone to causing systemic toxicity to effectively
prevent dose-limiting side effects and improve therapeutic efficiency of the drugs.
Accordingly, various SN-38 prodrug platforms have been reported. For example,
polyethylene glycol (PEG)-conjugate of SN-38 (EZN-2208) reached clinical trials for
triple negative breast cancer for its increased solubility and prolonged biological halflife.9 Similarly, PEG-poly(glutamate)-SN38 conjugate (NK012) demonstrated selfassembly capability into micelles with enhanced solubility, half-life, and drug
accumulation in tumors via the presumed enhanced permeation and residence (EPR)
effect.10 Furthermore, quinone propionic acid (QPA) trigger was conjugated to SN-38 for
redox-stimulus activation of the drug at tumor sites with upregulated level(s) of a
detoxifying redox enzyme called NAD(P)H:quionone oxidoreductase 1 (NQO1 or DTdiaphorase).11 Here, the respective enzyme could mediate a two-electron reduction of the
trigger and intact SN-38 was released upon its cleavage. Likewise, arylnitro groups such
as p-nitrobenzyl and 2-nitroimidazole were also incorporated as redox-triggers in the
syntheses of hypoxia-sensitive bioreductive SN-38 prodrugs. 12 Upon successful
reduction, the arylnitro moieties could transform into arylamines that spontaneously
initiated intramolecular electron pushing processes to release intact SN-38.
Herein, we report synthesis of DNS-SN38, a novel bimodal SN-38 prodrug that is
activatable in the presence of glutathione (GSH). GSH is an endogenous tripeptide, found
predominantly in the intracellular regions, that plays crucial roles in important cellular
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functions. It is widely recognized that GSH concentrations in hypoxic tumor
microenvironments are notably higher than those in normal cells

13

and thus, furnishing

GSH-sensitivity in anticancer prodrug design is a trending paradigm in the industry. In this
prodrug, 2,4-dinitrobenzene sulfonyl (DNS) moiety is conjugated as the cleavable trigger
via nucleophilic addition of the sulfhydryl (R-SH) group in the biothiols, such as
glutathione (GSH) and cysteine (Cys). Recently, the DNS moiety has emerged as a useful
trigger for the design of thiol-sensitive prodrugs and fluorescent imaging probes.14 This
trigger group was found to be particularly noteworthy in our study, where it was conjugated
to the hydroxyl (–OH) group at C10 site of SN-38, as it virtually quenched the drug’s
inherent fluorescence. According to previously reported systems that utilized DNS, such
fluorescence quenching mechanism was attributed to either donor-excited photo-induced
electron transfer (d-PeT)

15

or intramolecular charge transfer (ICT)

16

, in which the strong

electron withdrawing potential of DNS allowed transfer-acceptance of excited electron
from the conjugated fluorophore. Thus, the thiols-mediated cleavage of DNS was expected
to not only release intact SN-38 in the intracellular compartment, but also simultaneously
restore the fluorescence of SN-38 to achieve both anticancer therapy as well as diagnostic
molecular imaging of the drug. As such, we have investigated DNS-SN38’s potential as a
bimodal chemotherapeutic agent by studying its thiol-triggered activation through
fluorescence restoration and cytotoxicity in comparison to that of SN-38.
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CHAPTER 2: EXPERIMENTAL
Materials
SN-38 (7-ethyl-10-hydroxyl-camptothecin) was purchased from Carbosynth, LLC (San Diego,
CA). 2,4-dinitrobenzene sulfonyl chloride and triethylamine (TEA) was purchased from Alfa
Aesar (Ward Hill, MA). All other chemicals and solvents were purchased from Fisher Scientific
(Pittsburgh, PA).

1. Synthesis of DNS-SN38
SN-38 (0.255 mmol, 1 eq.) was first dissolved in 10 mL of anhydrous DCM and excess TEA
was added (0.765 mmol, 3.0 eq.). The mixture was then lowered to 0oC and stirred for 15
minutes. Next, 2,4-dinitrobenzene sulfonyl chloride (0.3 mmol, 1.2 eq.) dissolved in 5 mL of
anhydrous DCM was added to the mixture slowly in drop-wise fashion over 30 minutes.
Once addition was finished, the reaction mixture was left to stir for additional 1.5 hours at
0oC. After monitoring the reaction progress via TLC, the organic phase was washed with
saturated NaHCO3 solution and brine. The organic phase was then concentrated under
vacuum and crude product was recrystallized with acetone to yield slightly-yellow solid
powder as the final product. (%Yield = 65%)
2.

1

H NMR and HPLC Characterization of DNS-SN38

1

H NMR (Bruker Avance, 400 MHz, DMSO-d6; ppm): 9.14 (d, 1H), 8.59 (dd, 1H), 8.35 (d, 1H),

8.23 (d, 1H), 8.05 (d, 1H), 7.66 (dd, 1H), 7.34 (s, 1H), 5.44 (s, 2H), 5.34 (s, 2H), 3.13 (q, 2H), 1.87
(m, 2H), 1.17 (tr, 3H), 0.87 (tr, 3H).
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High performance liquid chromatography (HPLC) was utilized to characterize DNS-SN38 in
comparison to SN-38. Waters (Milford, MA) HPLC system (λDetection = 365 nm) with Waters
1525 binary pump, Waters 717plus auto sampler, Waters 2487 UV detector, and
Phenomenex Luna C18 column (150x4 60 mm, 5 micron). The mobile phase was 25 mM
NaH2PO4 (pH 3.1):ACN = 50:50 (v/v) eluting at a flow rate of 1.0 ml/min. All samples were
filtered with 0.45 µM filters before injection into HPLC system.
3. UV-Vis Spectroscopy
The UV-Vis spectroscopy was performed for both DNS-SN38 and SN-38 using Genesys 10S
UV-Vis Spectrophotometer from Thermo Fisher Scientific (Waltham, MA) in DMSO:PBS
(pH 7.4) = 1:2 (v/v) solution.
4. GSH-Activation of DNS-SN38 via Fluorescence Restoration
For this study, LC500 Fluorescence Spectrophotometer from Perkin-Elmer (Waltham, MA)
was used for fluorescence measurements. Based on the result of UV-scan of both SN-38 and
DNS-SN38, the excitation wavelength was set at 365 nm. The solution used to prepare SN38 and DNS-SN38 stock samples was DMSO:PBS (pH 7.4) = 1:2 (v/v) solution. Appropriate
dilutions of these stock samples were carried out with the same solution. For time-dependent
studies, FL WinLab software’s kinetic study mode was utilized with consistent delay of 60
seconds between the scans. The first scan was made 30 seconds after GSH injection into
sample solution.
5. Fluorescence Imaging of DNS-SN38 in B16-F10 cells
For tracking of internalization of SN-38 in B16F10 cells, confocal images were obtained on a
Nikon TiE confocal microscope using the NIS-Elements software. B16F10 at a density of 1 X
105 cells per well were seeded on the coverslips in 24 well plate under the standard conditions
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at 37 oC with 5 % CO2 and 100 % humidity. When the cell confluency was around 90 %, 10
μM DNS SN-38 was treated four wells and another well without DNS SN-38 was used for
control. Then, cells were incubated for 1, 5, 15, and 30 mins. For cell fixation, all media were
aspirated at different time points and washed with 1 mL of PBS for 5 min. Then, 500 μL of 4 %
PFA was treated at room temperature for 10 minutes. All wells were rinsed with 1 mL of PBS
for three times. Then, 500 μL of DAPI was added to all wells and incubated at room
temperature for 10 min. All DAPI solution was removed and washed with 1 mL of PBS for 5
min. Then, the coverslip was mounted on the slide glass for confocal microscopy.
The reported percentage values were normalized DNS SN-38 fluorescence intensity compared
to the DAPI intensity. ImageJ software was used to measure the mean gray values of DAPI
and SN-38 from four different regions. The normalized DNS SN-38 fluorescence intensity is
given by the following equation:

Normalized DNS SN 38 (%) = �

𝐷𝐷𝐷𝐷𝐷𝐷 𝑆𝑆𝑆𝑆 38 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖
� × 100
𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖

6. Cytotoxicity Test On Ovarian Cancer Cell Lines: A2780 & mCherry + OCSC1-F2
The A2780 ovarian cancer cells were seeded into 96-well plates at 1 x 104 cells/well and
incubated at 37 °C overnight before experiments. After cells were attached to the plates,
different concentrations (0.01, 0.1, 1, 10, 100, 1,000, and 10,000 nM) of DNS-SN38 and SN38 were incubated with cells for 48 hours, followed by the MTT assay. The absorbance was
determined at 570 nm with a reference wavelength of 630 nm by a microplate reader.
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Similar process was applied to the mCherry-labeled ovarian cancer cell line OCSC1-F2,
which was generated and propagated as previously described. The excitation for mCherry
was carried out at 550 nm with emission at 635 nm.
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CHAPTER 3: RESULTS AND DISCUSSION
The synthetic route for the prodrug is depicted in Scheme 1. By precisely controlling
the reagent ratio, temperature, and addition rate, selective conjugation of DNS to the
phenolic hydroxyl group (10’ –OH) was accomplished. In addition to 1H NMR validation,
we utilized HPLC to confirm the success of respective modification. Based on the
detection conditions listed in details in the experimental section, the elution times for SN38 and DNS-SN38 were determined to be 2.1 minutes and 8.6 minutes, respectively.
Considering chromatography was performed in reversed-phase, this result indicated that
DNS-SN38 was more hydrophobic than SN-38. Such alteration may be explained by the
masking of polar hydroxyl group with relatively non-polar DNS moiety. Previously, SN38 has been modified with various hydrophobic groups, such as oleic acid, valine, and αtocopherol to increase lipid solubility of the drug. The potential benefits of such
modifications were: enhanced drug loading efficiency in lipid-based formulations and
improved permeability through the cell membranes. Although DNS moiety’s
hydrophobicity may not be on par with the aforementioned groups, its presence may still
be sufficient enough to extend out to lipid-based delivery systems in future studies.
The large variation in cytotoxic potency between the CPT analogues is known to be
caused by their differences in structural arrangements and/or substitutions. For example,
the presence of a chiral center at C20 creates 20S- and 20R-isomers, where S-form exhibits
up to 100-fold potency relative to its counterpart. In the case of SN-38, the hydroxyl
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group substituted at C10 – along with ethyl group at C7 – enhances drug stability in
physiological conditions, which largely contributes to SN-38’s unparalleled cytotoxicity.
For that, masking of this hydroxyl group via covalent conjugation has proven to
significantly lower toxicity of the drug as exemplified by several cases such as CPT-11
and SN38-glucuronide (SN38G). Based on this, DNS-SN38 is expected to sufficiently
follow the most fundamental principle of prodrugs – pharmacological inertness prior to
activation.
In order to test our hypothesis on thiol-activation of the synthesized prodrug, 2 µM of
DNS-SN38 was treated with 1 mM GSH in DMSO:PBS (10 mM, pH 7.4) solution at 37
o

C. After 10 minutes of incubation, the sample was immediately analyzed via HPLC. In

the resulting chromatogram, Figure 2, the characteristic peak at 8.6-minute representing
DNS-SN38 was absent, but a new peak appeared at 2.1-minute which was previously
characterized to represent SN-38 standard. As the control group (without GSH-treatment)
remained intact in the same incubation conditions, such result indicated that GSHtreatment could indeed cleave the DNS-trigger from DNS-SN38 via nucleophilic
substitution of sulfhydryl group present in GSH and thereby release intact SN-38.
Encouraged by this preliminary study, DNS-SN38’s activation was further studied in
terms of fluorescence quenching and restoration. As mentioned previously, we predicted
that the covalent conjugation of DNS-trigger to the hydroxyl group at C10 site of SN-38
would quench the inherent fluorescence of the drug at 556 nm due to d-PeT/ICT process.
Therefore, we first examined the optical properties of DNS-SN38 in comparison to those
of SN-38. The UV-absorption spectroscopy of DNS-SN38 and SN-38 revealed that the
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absorption maxima for both compounds overlapped at 365 nm and 380 nm (Figure 1). As
such, the excitation wavelength (λexcitation) was set at 365 nm for the fluorescence study.
In accordance to our prediction, the fluorescence emission at 556 nm of 20 µM SN-38
was measured to be 41-times higher than that of 20 µM DNS-SN38 in DMSO:PBS (10
mM, pH 7.4) medium as depicted in Figure 3. Next, in order to verify thiol-sensitive
prodrug activation, 20 µM DNS-SN38 sample was treated with 100 µM GSH and
fluorescence restoration was monitored in a time-dependent manner Figure 4. Consistent
with the preliminary study carried out using HPLC, the activation of DNS-SN38
completed within 10 minutes, as the plateau fluorescence intensity was reached by the
9.5-minute mark. Considering [GSH:DNS-SN38] molar ratio was much lower in our
fluorescence activation study [10:2] than in preliminary HPLC study [1000:2], such rapid
activation rate suggested that thiol-sensitive DNS-cleavage do not require significant
excess of biothiols.
Motivated by such indication, we next assessed fluorescence activation/restoration of
DNS-SN38 in a GSH concentration-dependent manner in similarly prepared conditions.
As shown in Figure 5, an array of GSH concentrations (20, 40, 60, and 100 µM) was
tested against 20 µM of DNS-SN38, where the fluorescence activation rate indeed
increased along with increase in GSH concentrations. Furthermore, the rapid activation
trend observed in previous studies remained unchanged, as the plateau fluorescence
intensity was reached within 10 minutes for all tested samples. However, it was notable
that the maximum/plateau fluorescence intensity of 20 µM GSH sample [1:1] was around
82% of those of remaining samples with higher GSH content, which indicated that slight
molar excess of GSH over DNS-SN38 is still required in order to induce complete
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activation of the prodrug. Lastly, the control group (without GSH-treatment) remained
quenched in fluorescence intensity in same incubation conditions, clearly confirming that
fluorescence restoration was induced by GSH.
These results collectively showed that GSH-dependent activation of DNS-SN38 is
highly efficient and rapid. Although the results obtained from such simulated in vitro
conditions cannot be used as the sole reference to conclude about in vivo conditions, they
were sufficient to make a rational prediction that DNS-SN38 activation at tumor sites –
with GSH in millimolar (10-3 M) range – is extremely probable. Such activation trend was
also in conjunction to previous reports on DNS-based molecules intended for biothiolsensitivity.
Next, we examined real-time drug monitoring capability of DNS-SN38 by
demonstrating the prodrug’s fluorescence response in B16F10 cell line, stained with
DAPI, via confocal microscopy (Figure 6). Here, 10 µM of DNS-SN38 was incubated
with 104 cells. As Figure 6 shows, rapid fluorescence activation was observed from the
cells over 30 minutes. Furthermore, merging of DAPI fluorescence and activated DNSSN38 fluorescence images revealed that DNS-SN38 was indeed internalized and
activated in the cytosol as the green fluorescence of SN-38 surrounded the blue
fluorescence of DAPI. Considering DAPI was used to stain the cell nuclei, it was evident
that the prodrug was activated once it was internalized into the cell cytosol. Taken
together, it was clear that DNS-SN38 activation could be achieved at tumor sites at a very
rapid rate. However, considering normal cells also consist of adequate levels of GSH,
targeted chemotherapy using DNS-SN38 would be most ideal when supplemental
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delivery vehicle(s) can be implemented to exploit passive-targeting via the enhanced
permeation and retention (EPR) effect.
To further evaluate anticancer activity of DNS-SN38, we then carried out 48-hour cell
viability tests in comparison to SN-38 on A2780 and mCherry+OCSC1-F2 (mCherrylabeled ovarian cancer stem cell) lines in MTT assay (Figure 8). The results displayed
extremely potent anticancer profiles of DNS-SN38 on both cell lines, which were nearly
identical to the profiles of SN-38. The corresponding IC50 (50% inhibitory concentration)
values were determined to be within 10 nM against both cell lines. Considering SN-38’s
parent drug, CPT, typically displays IC50 in micro-molar range, resulting cytotoxicity of
DNS-SN38 proved to be superior and comparable to that of intact SN-38. Moreover, such
result further validated the activation efficiency of DNS-SN38 in agreement to the results
of our previous experiments.

Scheme 1. Synthetic scheme for DNS-SN38
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Scheme 2. Schematic illustration of DNS-SN38 fluorescence activation in the presence of
biothiols. The quenched fluorescence of SN-38 is resumed upon DNS-cleavage by thiol
substitution.

Figure 1 UV-absorbance spectra of DNS-SN38 and SN-38 in DMSO:PBS (pH 7.4) = 1:2 (v/v).
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Figure 2. HPLC chromatograms of DNS-SN38, GSH-treated (10 minute) DNS-SN38, and SN-38
standard.

Figure 3. Fluorescence emission at 556 nm (λexcitation= 365 nm) of SN-38 standard and quenched
emission of DNS-SN38.
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Figure 4. Fluorescence activation of DNS-SN38 with 100 µM GSH over 9.5 minutes with
consistent 60-second measurement intervals.
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Figure 5. GSH concentration (control or 0, 20, 40, 60, 100 µM)-dependent fluorescence
activation rate of DNS-SN38 (20 µM). The error bars represent standard deviation (n=3).
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Figure 6. Confocal microscopy images with the different time points of B16F10 cells incubated
with 10 μM of DNS SN-38 and DNS SN-38 fluorescence intensity analysis. B16F10 cells exposed
to 10 μM of DNS SN-38 for 1, 5, 15, and 30 min were stained with DAPI and imaged by a Nikon
TiE confocal microscope using the NIS-Elements software. Green fluorescence shows the location
of DNS SN-38. DAPI staining was used for the nucleus (blue). Expanded images represent the
region of interest (ROI) which is the yellow box of the merged images. Scale bar of DAPI, DNS
SN38, and merged images corresponds to 100 μm. Scale bar of the expanded image corresponds
to 20 μm.
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Figure 7. Normalized DNS SN-38 fluorescence intensities were calculated by ImageJ software
from different regions (n=4).
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Figure 8. (A) 48-hour cell viability profiles for A2780 cell line treated with either DNS-SN38 or
SN-38 at varying concentrations (nM); (B) 48-hour cell viability profiles for mCherry+OCSC1F2 cell line treated with either DNS-SN38 or SN-38 at varying concentrations (nM). The error
bars represent standard deviation (n≤3).
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CHAPTER 4: CONCLUSIONS
In summary, we report successful synthesis and preliminary characterization of a novel SN-38
prodrug called DNS-SN38. By covalently masking 10’ –OH site of SN-38 using 2,4dinitrobenzensulfonyl (DNS) group, a highly thiol-sensitive anticancer prodrug with quenched
fluorescence via d-PeT was yielded. Upon nucleophilic substitution of sulfhydryl group in
biothiols, the DNS-trigger could be rapidly cleaved off and thereby release intact SN-38 with
restored fluorescence. Through various studies, we have demonstrated the prodrug’s capability
for real-time monitoring of drug distribution and its extremely potent cytotoxicity upon
activation. Thus, we propose DNS-SN38 as a viable agent that can potentially translate into a
useful chemotherapeutic option against various types of cancer.
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